Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions (MITOSKIN)
Primary Purpose
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinomas
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
biopsy
Sponsored by
About this trial
This is an interventional diagnostic trial for Cutaneous Squamous Cell Carcinoma focused on measuring Actinic keratosis, mitochondria, metabolism
Eligibility Criteria
Inclusion Criteria:
Every patient with suspected lesion :
- AK,
- in situ cSCC,
- infiltrative cSSC
- cSCC with recurrent disease
- cSCC with cutaneous metastases.
- Patients 18 years of age or older,
- Patients with suspected AK or BCC lesions (in situ, infiltrating or metastatic),
- Patient able to sign a consent form,
- Patient affiliated with a Social Security system.
Exclusion Criteria:
- Prior systemic treatment such as checkpoint inhibitors or chemotherapy.
- Patients with cSCC or AK localized on visible zone of the face or folds
Sites / Locations
- Hôpital Saint-André - CHU de BordeauxRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Experimental
Arm Label
Patients with actinic keratoses
patients with squamous cell carcinoma in situ
patients with squamous cell carcinomas
patient with invasive metastates
Arm Description
Outcomes
Primary Outcome Measures
Proportion of patients who have a glycolysis profile (proteomic analysis liquid chromatography-mass spectrometry (LC-MS/MS))
Metabolic profiling of different stages of carcinogenesis: glycolysis, oxidative phosphorylation
Proportion of patients who have an oxidative profile (proteomic analysis liquid chromatography-mass spectrometry (LC-MS/MS))
Metabolic profiling of different stages of carcinogenesis: glycolysis, oxidative phosphorylation
Secondary Outcome Measures
Evaluation of skin differentiation markers
% of samples in each category (AK, in situ, ...) that present differentiation features are assessed by immunostaining of loricrin, filaggrin, K10
Evaluation of cSCC aggressiveness markers
% of samples expressing aggressive markers will be assessed by evaluating the proliferation index, degree of differentiation, invasion beyond subcutaneous fat, perineural invasion, vascular invasion level of infiltration following immunohistochemistry analyses on formalin-fixed paraffin-embedded tissue sections.
Evaluation of skin apoptotic markers
% of samples with high apoptotic cell death level will be assessed by immunostaining using antibody against cleaved caspase-3.
Evaluation of mitochondrial metabolism on skin biopsies
% of samples with high mitochondrial activity will be evaluated by comparing oxygen consumption rate by different fresh samples.
Evaluation of cancer proliferative features on skin biopsies
% of samples that are highly proliferative will be calculated by measuring the ability of colony formation (SRB Test) and cell cycle progression (flow cytometer, western).
Full Information
NCT ID
NCT04389112
First Posted
March 31, 2020
Last Updated
November 22, 2022
Sponsor
University Hospital, Bordeaux
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
1. Study Identification
Unique Protocol Identification Number
NCT04389112
Brief Title
Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions
Acronym
MITOSKIN
Official Title
Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 28, 2020 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Skin carcinomas are the most frequent cancers in the world, including basal cell carcinomas and cutaneous squamous cell carcinoma (cSCCs), with more than 60.000 new annual cases in France. Their incidence increases mainly due to ultraviolet (UV) exposure and population ageing. Then from 1994 to 2006, the incidence of cSCC has increased by 300%. CSCCs typically manifests as a spectrum from a precursor actinic keratosis (AK) - possible spontaneous regression at this stage- to in situ cSCC invasive cSCC and finally metastatic cSCC.
Detailed Description
Although growing evidence indicates that bioenergetic metabolism plays an important role in the progression of tumorigenesis, little information is available on the contribution of reprogramming of energy metabolism in cancer initiation and how it influences further the bioenergetic behavior of tumors.
By applying a quantitative proteomic approach, the consortium has recently found that specific metabolic modifications precede cSCC.
This study will investigate the role of energy metabolism in malignant transformation of premalignant skin lesions into cSCC, and in cSCC progression, with correlation with clinical characteristics and metastatic outcomes. Using several cutting-edge technologies in human samples, the team will evaluate whether targeting energy metabolism has the potential to be used as curative treatments for cSCC and whether pre-determined metabolic alterations could be exploited as new preventive strategies. These modifications in energy metabolism could be used as prognostic and diagnostic biomarkers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinomas
Keywords
Actinic keratosis, mitochondria, metabolism
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Patients with actinic keratoses
Arm Type
Experimental
Arm Title
patients with squamous cell carcinoma in situ
Arm Type
Experimental
Arm Title
patients with squamous cell carcinomas
Arm Type
Experimental
Arm Title
patient with invasive metastates
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
biopsy
Intervention Description
Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.
Primary Outcome Measure Information:
Title
Proportion of patients who have a glycolysis profile (proteomic analysis liquid chromatography-mass spectrometry (LC-MS/MS))
Description
Metabolic profiling of different stages of carcinogenesis: glycolysis, oxidative phosphorylation
Time Frame
Day 1
Title
Proportion of patients who have an oxidative profile (proteomic analysis liquid chromatography-mass spectrometry (LC-MS/MS))
Description
Metabolic profiling of different stages of carcinogenesis: glycolysis, oxidative phosphorylation
Time Frame
Day 1
Secondary Outcome Measure Information:
Title
Evaluation of skin differentiation markers
Description
% of samples in each category (AK, in situ, ...) that present differentiation features are assessed by immunostaining of loricrin, filaggrin, K10
Time Frame
Day 1
Title
Evaluation of cSCC aggressiveness markers
Description
% of samples expressing aggressive markers will be assessed by evaluating the proliferation index, degree of differentiation, invasion beyond subcutaneous fat, perineural invasion, vascular invasion level of infiltration following immunohistochemistry analyses on formalin-fixed paraffin-embedded tissue sections.
Time Frame
Day 1
Title
Evaluation of skin apoptotic markers
Description
% of samples with high apoptotic cell death level will be assessed by immunostaining using antibody against cleaved caspase-3.
Time Frame
Day 1
Title
Evaluation of mitochondrial metabolism on skin biopsies
Description
% of samples with high mitochondrial activity will be evaluated by comparing oxygen consumption rate by different fresh samples.
Time Frame
Day 1
Title
Evaluation of cancer proliferative features on skin biopsies
Description
% of samples that are highly proliferative will be calculated by measuring the ability of colony formation (SRB Test) and cell cycle progression (flow cytometer, western).
Time Frame
Day 1
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Every patient with suspected lesion :
AK,
in situ cSCC,
infiltrative cSSC
cSCC with recurrent disease
cSCC with cutaneous metastases.
Patients 18 years of age or older,
Patients with suspected AK or BCC lesions (in situ, infiltrating or metastatic),
Patient able to sign a consent form,
Patient affiliated with a Social Security system.
Exclusion Criteria:
Prior systemic treatment such as checkpoint inhibitors or chemotherapy.
Patients with cSCC or AK localized on visible zone of the face or folds
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marie BEYLOT-BARRY, MD, PhD
Phone
+335 57 82 25 00
Email
marie.beylot-barry@chu-bordeaux.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Léa DOUSSET, MD
Phone
+335 57 82 25 00
Email
lea.dousset@chu-bordeaux.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie BEYLOT-BARRY, MD, PhD
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Saint-André - CHU de Bordeaux
City
Bordeaux
ZIP/Postal Code
33000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie BEYLOT-BARRY, MD, PhD
Phone
+335 57 82 25 00
Email
marie.beylot-barry@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Christine ALFARO
Phone
+335 56 82 06 55
Email
christine.alfaro@chu-bordeaux.fr
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
25542180
Citation
Obre E, Rossignol R. Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. Int J Biochem Cell Biol. 2015 Feb;59:167-81. doi: 10.1016/j.biocel.2014.12.008. Epub 2014 Dec 24.
Results Reference
background
PubMed Identifier
29925003
Citation
Hosseini M, Dousset L, Mahfouf W, Serrano-Sanchez M, Redonnet-Vernhet I, Mesli S, Kasraian Z, Obre E, Bonneu M, Claverol S, Vlaski M, Ivanovic Z, Rachidi W, Douki T, Taieb A, Bouzier-Sore AK, Rossignol R, Rezvani HR. Energy Metabolism Rewiring Precedes UVB-Induced Primary Skin Tumor Formation. Cell Rep. 2018 Jun 19;23(12):3621-3634. doi: 10.1016/j.celrep.2018.05.060.
Results Reference
background
PubMed Identifier
31551419
Citation
Hosseini M, Dousset L, Michon P, Mahfouf W, Muzotte E, Bergeron V, Bortolotto D, Rossignol R, Moisan F, Taieb A, Bouzier-Sore AK, Rezvani HR. UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis. Oncogenesis. 2019 Sep 24;8(10):52. doi: 10.1038/s41389-019-0161-z.
Results Reference
background
PubMed Identifier
30878676
Citation
Mahfouf W, Hosseini M, Muzotte E, Serrano-Sanchez M, Dousset L, Moisan F, Rachidi W, Taieb A, Rudolf J, Rezvani HR. Loss of Epidermal HIF-1alpha Blocks UVB-Induced Tumorigenesis by Affecting DNA Repair Capacity and Oxidative Stress. J Invest Dermatol. 2019 Sep;139(9):2016-2028.e7. doi: 10.1016/j.jid.2019.01.035. Epub 2019 Mar 13. Erratum In: J Invest Dermatol. 2022 May;142(5):1506-1507.
Results Reference
background
Learn more about this trial
Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions
We'll reach out to this number within 24 hrs